Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9632)	4/15/1999 10:10:00 AM
From: Slugger	Read Replies (1) \| Respond to of 17367

<<Genentech will fund XOMA's share of development costs via long-term convertible loans.>>=more dilution. I would like to know more about the terms of this agreement. On the positive side, Genentech doesn't think XOMA is going out of business anytime soon (or they expect to buy them out).

To: Robert K. who wrote (9632)	4/15/1999 10:14:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Pleased with the announcement, but convinced XOMA was trying to time its' release with Castello's presentation. I can understand the desire to to this. But cannot understand, "lying" about the details not being complete. Would have felt better if XOMA had just said we had agreed on the timing of this release and GNE came out a bit earlier. This would keep some of us from going wild and mad trying to cut through the bull. XOMA is IMO a great company. Will the stock go up? Don't know. Previous convertible financing with GNE was floorless type financing, so I want to see the details on this. Also no mention of milestones, and note the sharing is 25% not 50% as posted by #1 Bitchinheat.